Management of mitochondrial proteins: sort or destroy

Add to your list(s) Download to your calendar using vCal

• Professor Agnieszka Chacinska
• Thursday 17 January 2019, 15:00-16:00
• Sackler Lecture Theatre (Level 7) Wellcome Trust/MRC Building, Cambridge Biomedical Campus.

If you have a question about this talk, please contact Hannah Burns.

Mitochondria are multifunctional organelle, primarily involved in fundamental biological process, respiration. The efficient functioning of mitochondria depends on the proper transport, sorting and assembly of mitochondrial proteins that originate either from nuclear or mitochondrial genomes. Both nuclear and mitochondrial genome defects resulting in mutated proteins have been implicated in variety of mitochondrial diseases. The nuclear encoded proteins make up for the large majority of the proteins involved in formation of mitochondria including the respiratory chain complexes. The ubiquitin – proteasome system (UPS) in cytosol is largely involved in degradation of cellular proteins and maintaining protein homeostasis. By multiple lines of evidence we have demonstrated the contribution of UPS to mitochondrial IMS protein quality control. The UPS degrades a portion of mitochondrial proteins including mislocalised proteins, in both yeast and mammalian systems. Furthermore, mislocalization of mitochondrial proteins increases the ability of the proteasome to degrade cellular proteins. Thus, the UPS constitutes an important factor that influences mitochondrial proteome in physiology and links mitochondrial status with regulation of cellular protein homeostasis. Malfunctioning of mitochondria is a cause of devastating mitochondrial disease. Pathologic variants of mitochondrial proteins can be mistargeted and fully degraded by the proteasome before they reach their final destination inside mitochondria. Inhibition of proteasomal degradation by commonly used proteasome inhibitors leads to rescue of proteins and their import into mitochondria. Thus, UPS inhibition can provide a benefit to malfunctioning mitochondria. We propose that targeting the UPS should be considered as a therapeutic strategy for mitochondrial diseases.

This talk is part of the MRC Mitochondrial Biology Unit Seminars series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• CamBridgeSens
• Cambridge talks
• Life Science Interface Seminars
• MRC Mitochondrial Biology Unit Seminars
• Sackler Lecture Theatre (Level 7) Wellcome Trust/MRC Building, Cambridge Biomedical Campus
• Trust & Technology Initiative - interesting events

Note that ex-directory lists are not shown.